Skip to main content

Home/ Online Pharmacy Store - Pharmacy Discounts UK/ Group items tagged disorder

Rss Feed Group items tagged

pharmacybiz

Weight Loss Drugs May Reduce Risk of Substance Disorders | Pharmacy Biz News 2025 - 0 views

  •  
    A comprehensive cohort study has shed light on the benefits and risks associated with weight-loss drugs, offering valuable insights for clinical care and future research. Published in Nature Medicine on 20 January 2024, the study found the use of glucagon-like peptide 1 receptor agonists (GLP-1RAs)-used to treat diabetes and obesity-associated with a reduced risk of substance use disorders (including alcohol, cannabis, opioid and stimulant use disorders). Weight-loss drug use was also linked to decreased risks of psychotic disorders, seizures, neurocognitive disorders (including Alzheimer's disease and dementia), coagulation disorders, cardiometabolic disorders, infectious illnesses and several respiratory conditions. However, the use of GLP-1RAs was not without risks, as researchers identified an increased risk of gastrointestinal disorders, hypotension, syncope, arthritic conditions, nephrolithiasis, interstitial nephritis, and drug-induced pancreatitis associated with their use. The analysis, utilising the U.S. Department of Veterans Affairs databases, compared 215,970 GLP-1 RA users with patients using sulphonylureas (n=159,465), DPP4 inhibitors (n=117,989), SGLT2 inhibitors (n=258,614), or a composite of the three (n=536,068).
pharmacybiz

Urgent Call for Sickle Cell Awareness: PDA Report 2024 Highlights Pharmacists' Knowledg... - 0 views

  •  
    Despite being the most common genetic disorder in the UK, sickle cell disease (SCD) remains significantly underfunded and underserved compared to other genetic disorders, according to a new report published by the PDA BAME (Black, Asian and Minority Ethnic) Pharmacists' Network. The report also reveals that the disease is poorly understood within the healthcare system, including amongst pharmacists, pharmacy students, and foundation pharmacists in the UK. It emphasises the urgent need for increased awareness, funding, and improved healthcare access for SCD amongst these healthcare professionals. "A lack of education about SCD within the wider healthcare community, including pharmacy, greatly contributes to disparities in care. "Though the importance of SCD education for pharmacists and allied healthcare professionals is acknowledged, it remains unclear whether this topic is adequately addressed within the MPharm curriculum," the report said. The report further noted that in the absence of explicit guidance from the General Pharmaceutical Council (GPhC) or the Pharmaceutical Society of Northern Ireland (PSNI) and without more comprehensive education surrounding SCD embedded within the pharmacy curriculum, pharmacists and future pharmacists may remain "ill-prepared to manage patients with this complex condition." As per the report, sickle cell disease is the most prevalent genetic disorder globally, impacting millions, including around 17,000 people in England.
Kamagrauk1 UK

When Your Sex Drive is all but Eradicated, Buy Kamagra - 0 views

  •  
    As with most health issues, it is not recommended that you hope it will go away on its own. If you have ED and it is a manifestation of another more serious health disorder such as diabetes or atherosclerosis, it is better to have it seen to as soon as possible. You may find that as soon as your disorder is attended to the ED desists. If not taking Kamagra is an excellent ED choice.
pharmacybiz

United Pharmacy Bodies Condemn Racism Amid UK Riots 2024 | Stand Together for Equality - 0 views

  •  
    The General Pharmaceutical Council (GPHC), Royal Pharmaceutical Society (RPS), Company Chemists Association (CCA), Association of Pharmacy Technicians UK (APTUK), National Pharmacy Association (NPA), Guild of Healthcare Pharmacists, Pharmacists' Defence Association (PDA), and Independent Pharmacies Association (IPA) have released a joint statement in response to the far-right riots across the UK. They emphasised their united stance, declaring zero tolerance for racism towards colleagues or the public in any form. The joint statement reads: "We are shocked and saddened by the violent public disorder events in recent days. "We acknowledge how all sectors of the pharmacy profession may be impacted and recognise the challenges that this level of overt aggression can have on people's ability or willingness to live their daily lives. "The pharmacy workforce deserves peace and safety, not fear and harm. We stand united in having a zero tolerance of racism towards our colleagues or the public in whatever form it takes." Meanwhile, Community Pharmacy England (CPE) has expressed concerns that protests and violent disorder in various towns and cities across England may impact the ability of community pharmacies to operate.
pharmacybiz

GPhC Condemns Racism and Violence Against UK Pharmacy Staff - 0 views

  •  
    The General Pharmaceutical Council (GPhC) has strongly condemned recent acts of racism, violence, and disorder caused by far-right, anti-immigrant protestors across the UK. Roz Gittins, chief pharmacy officer at GPhC, expressed deep concern for the safety of pharmacy teams, particularly those from Black and minority ethnic backgrounds. He said: "We strongly condemn the racism, violence and disorder caused by a small minority of the population that has taken place over recent days." "We understand that pharmacy teams serving our communities may feel especially vulnerable at this time." "Pharmacists and pharmacy technicians from black and minority ethnic backgrounds, as well as those who trained abroad, make an enormous contribution to our pharmacy and health services and they should never have to feel fear when going to work.
pharmacybiz

DHSC & MHRA Act: Curbing Hoarding & Supplying ADHD Drugs - 0 views

  •  
    The Department of Health and Social Care (DHSC) and the Medicines and Healthcare Products Regulatory Agency (MHRA) have added five more medicines that cannot be hoarded or exported from the UK market. The government has taken the following action to address the "critical shortage" of attention deficit hyperactivity disorder (ADHD) drugs. In a crucial development on October 9, this strategic move aims to enable wholesalers to fulfil their legal obligation to supply these essential medicines to patients across the UK. The updated list of drugs incorporated "all" available strengths and pharmaceutical formulations, ensuring comprehensive coverage for patients' medical needs.
pharmacybiz

Revolutionary QbTest Transforms ADHD Diagnosis in UK Children - NHS Rollout 2024 - 0 views

  •  
    The NHS has started using a new digital test to accelerate the diagnosis of attention-deficit hyperactivity disorder (ADHD) in children, following successful trials by the National Institute for Health and Care Research (NIHR). In July 2024, the National Institute for Health and Care Excellence (NICE) issued draft guidance approving the use of QbTest by psychiatrists and specialist children's doctors to aid in ADHD diagnoses. This computerised test, which complements existing diagnostic methods, is expected to both improve assessment accuracy and save the NHS money. It is estimated that ADHD affects 3-5 per cent of school-age children, who show symptoms of inattention, impulsivity and hyperactivity. Professor Richard Morriss, NIHR ARC East Midlands Mental Health and Well-being Theme Lead, expressed concern that there has been a fourfold increase in ADHD referrals since the COVID-19 pandemic.
pharmacybiz

MHRA Fast-Tracks Approval of Joenja for Rare Immune Disease APDS - 0 views

  •  
    The Medicines and Healthcare products Regulatory Agency (MHRA) has on Friday approved leniolisib phosphate (Joenja) to treat a rare immune disease known as activated phosphoinositide 3-kinase delta syndrome or APDS in adults and adolescents aged 12-years-old and older who weigh 45kg or more. The medicine was approved via a fast-track approval process for medicines, known as the International Recognition Procedure (IRP), which allows the MHRA to consider the expertise and decision-making of trusted regulatory partners for the benefit of UK patients. The decision follows an approval for the drug by the US Food and Drug Administration (FDA). This is the first time the MHRA has approved a new medicine following FDA approval. The MHRA said it considered the assessment made by the US regulator as part of its own review, facilitating a rapid approval process. APDS is an inherited disorder where the patient is unable to fight infections because the immune system does not work properly. The main symptoms usually occur in the first two years of life and include repeated lung infections and a failure to grow and develop normally.
pharmacybiz

Urgent Quetiapine Shortage Response: New SSPs Issued by DHSC 2024 - 0 views

  •  
    In response to significant ongoing disruptions in the supply of certain Quetiapine tablet strengths, the Department of Health and Social Care (DHSC) on Tuesday issued nine new Serious Shortage Protocols (SSPs), with immediate effect. These measures aim to ensure the continued availability of quetiapine, an essential medication for managing schizophrenia and bipolar disorder. Under the new SSPs, community pharmacists are allowed to consider different options to manage the shortage of the three strengths of quetiapine tablets affected by ongoing supply disruptions: quetiapine 300mg tablets, quetiapine 200mg tablets, and quetiapine 150mg tablets. Depending on the prescribed quantity of the affected quetiapine tablet, pharmacists can either supply a reduced quantity of the same quetiapine tablet or substitute with an alternative strength or provide a reduced quantity of a specific alternative product.
pharmacybiz

ADHD Drug Prescriptions & Mental Health Medication Costs Rise in England - 0 views

  •  
    The NHS Business Services Authority (NHSBSA) has published its latest quarterly report on medicines used in mental health in England, specifically those used to treat anxiety, depression, psychosis, attention deficit hyperactivity disorder (ADHD), and dementia. Data from April to June 2024 show that 800,000 central nervous system (CNS) stimulants and ADHD drugs were prescribed to 230,000 identified patients. Both prescribing and dispensing of ADHD drugs continue to rise, with a 4.8 per cent increase in prescribed items and a 4.7 per cent rise in identified patients compared to the previous quarter. CNS stimulants and ADHD medications saw the largest increase in costs among the five drug categories, rising by 6.4 per cent to £36 million. The report reveals a modest increase in the prescribing of antidepressants, with 23 million antidepressant items prescribed to an estimated 6.9 million identified patients between April and June 2024. This represents a small increase of 1.5 per cent for prescribed items and a less than one per cent rise in identified patients compared to the previous quarter.
pharmacybiz

Pharmacists Seek Enhanced Safety Amidst Far-Right Riots - PDA Calls for Action | UK 2024 - 0 views

  •  
    The Pharmacists' Defence Association (PDA) has reported growing concerns among its members regarding their safety at work as the far-right, anti-immigration riots escalate across the UK. "We have received calls from members who are concerned about their safety at work and feel vulnerable in communities where the violence and disorder are taking place," the organisation told Pharmacy Business. The PDA also reported that some hospital outpatient departments and GP surgeries were forced to close their doors to allow staff to get home safely, which may impact services to patients. In light of these challenges, the PDA is calling on employers to ensure that they are adequately communicating with pharmacists in locations at risk of conflict and to prioritise the health and safety of staff and patients. "We are aware that pharmacists and their teams working in areas where this criminal activity is taking place are feeling vulnerable but that they also want to ensure that their communities are safe and have access to the vital services pharmacies provide.
pharmacybiz

Over Half of Pharmacy Teams Feel Unsafe Amid Riots - NPA Reports 2024 | Pharmacy Safety... - 0 views

  •  
    A snap survey conducted by the National Pharmacy Association (NPA) revealed that over half of community pharmacy teams have felt unsafe in the past week due to ongoing riots across the country. The survey, which included responses from approximately 350 community pharmacies, also found that one in three pharmacies had considered closing because of safety concerns, while 13 per cent of pharmacy teams reported experiencing racist comments during this period. According to the NPA, over 40 per cent of pharmacists are of South Asian, Black, or other ethnic minority backgrounds, with the majority of independent community pharmacy owners believed to be of South Asian heritage. The association reports that businesses had been vandalised during the riots, leading some pharmacies to reduce their opening hours or close entirely, following advice from the police and local authorities. Despite a recent decline in disorder over the last few days, police have been advised to remain on high alert over the weekend.
pharmacybiz

First licensed Lamotrigine oral liquid medicine available in the UK - 0 views

  •  
    New Lamotrigine Desitin 10mg/ml Oral Suspension is the first licensed Lamotrigine oral liquid medicine available in the UK, offering simple, accurate and flexible dosing for vulnerable patient groups with epilepsy and bi-polar disorder. Accurate dosing and slow titration are essential when initially prescribing for patients with epilepsy. This helps minimise the risk of potentially life-threatening side effects such as Stevens-Johnson syndrome (an acute, rare, and occasionally fatal skin reaction). Dose escalation is required every 2 weeks until the optimal dose is achieved to reach the desired maintenance level. Lamotrigine Desitin 10mg/ml Oral Suspension helps simplify complex prescribing and dispensing regimes, as all dosing requirements are covered in a single product. The supplied dosing syringe and cup make it simple for patients to use and carers to administer. The licensed Oral Suspension is likely to be of benefit when prescribing for children (over 2 years), older people (particularly patients with dysphagia) and also those with learning disabilities. The 10mg/ml strength simplifies accurate dosing for children and offers complete flexibility when dosing is based on mg/kg body weight.
supermedsuk

Buy zopiclone 10 mg - 0 views

  •  
    Zopiclone tablets 10 mg belong to the nonbenzodiazepine class of drugs used to treat insomnia. Click: https://www.supermeds.to/product/zopiclone-tablets-10-mg/ Phone: +442080895563 Email: info@supermeds.to
1 - 14 of 14
Showing 20 items per page